GenSight Biologics Reports Interim Financial Results for the First Half of 2021 and Provides Operational Update ATUs in France in Europe in H1 2022
Successful refinancing in Q1 2021 secures mid-2023 runway
Multiple regulatory and clinical milestones expected in Q4 2021
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its interim financial results for the first half of 2021 and provided recent operational updates. The full interim financial report is available on the Company s website in the Investors section. The 2021 half-year financial statements were subject to a limited review by the Company s statutory auditors and approved by the Board of Directors on July 28, 2021.
uniQure Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress
mobilitytechzone.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mobilitytechzone.com Daily Mail and Mail on Sunday newspapers.
COVID vaccine: India may be first country to develop DNA vaccine, says health min: How Zydus inoculant differs from others
timesnownews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from timesnownews.com Daily Mail and Mail on Sunday newspapers.
Annovis Bio, Inc : Annovis Bio Reports Positive Safety Data from its Phase 2 Alzheimer s Study
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.